Verrica Pharmaceuticals 2024第四季度调整后每股收益$(0.18)优于预期$(0.26),销售额$344.000K不及预期$1.041M

财报速递
12 Mar
Verrica Pharmaceuticals (纳斯达克代码: VRCA) 报告其季度每股亏损为$(0.18),优于分析师普遍预期的$(0.26),高出30.77%。公司报告季度销售额为$344.000千美元,低于分析师普遍预期的$1.041百万,减少了66.97%。与去年同期的$1.988百万销售额相比,下降了82.70%。

以上内容来自Benzinga Earnings专栏,原文如下:

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.26) by 30.77 percent. The company reported quarterly sales of $344.000 thousand which missed the analyst consensus estimate of $1.041 million by 66.97 percent. This is a 82.70 percent decrease over sales of $1.988 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10